Purpose: To evaluate effectiveness and safety information of transdermal fentanyl
(TDF)(Duragesic/Durogesic*) and sustained-release oral morphine (SRM) in cancer pain …

Objective: To determine the safety and efficacy of transdermal fentanyl for pain relief in
cancer patients and to compare the effects on patients according to whether they had …

Objective: The safety of transdermal fentanyl (TF) in comparison with slow-release oral
morphine (SROM) in moderate-severe pain was assessed. Design: A systematic review of …

Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18–
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …

Fentanyl is a synthetic opioid agonist which interacts primarily with the μ-opioid receptor.
The low molecular weight, high potency and lipid solubility of fentanyl make it suitable for …

There is emerging data supporting the use of TTS‐F (transdermal therapeutic system‐
fentanyl) in opioid naive patients. Our study examines the safety and efficacy of TTS‐F in the …

Objective: This randomised, multicentre, direct open comparative trial evaluated the efficacy,
treatment convenience, tolerability and safety aspects of transdermal therapeutic system …

Background Previous meta-analysis suggested that transdermal fentanyl was not inferior to
sustained-release oral morphine in treating moderate-severe cancer pain with less adverse …

To treat cancer pain, physicians often decide to jump directly from step 1 of the World Health
Organization (WHO) analgesic ladder to step 3. The use of transdermal fentanyl in patients …

We performed an open-label pilot study to define analgesic efficacy, acceptability, and
toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our …